National Board of Examinations

Question Paper Name :DrNB Medical Oncology Paper1Subject Name :DrNB Medical Oncology Paper1Creation Date :2023-04-25 11:44:47Duration :180Share Answer Key With Delivery Engine :NoActual Answer Key :No

DrNB Medical Oncology Paper1

Group Number: 1 Group Id: 327187738 **Group Maximum Duration:** 0 180 **Group Minimum Duration: Show Attended Group?:** Nο **Edit Attended Group?:** No **Group Marks:** 100 Is this Group for Examiner?: No **Examiner permission: Cant View Show Progress Bar?:** No

DrNB Medical Oncology Paper1

Section Id: 327187741

Section Number: 1

Section type: Offline

Mandatory or Optional: Mandatory

Number of Questions to be attempted: 10

Section Marks: 100

Enable Mark as Answered Mark for Review and

Clear Response:

Yes

Maximum Instruction Time: 0

Sub-Section Number: 1

Sub-Section Id: 327187745

Question Shuffling Allowed: No

Is Section Default?: null

Question Number: 1 Question Id: 32718720712 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time:0

Correct Marks: 10

- 1. a) Discuss the fundamental principles of radiobiology. [4]
- b) Principles of combining anticancer agents with radiation therapy. [3]
- c) Drugs that affect radiation sensitivity. [3]

Question Number: 2 Question Id: 32718720713 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

- a) Major types of somatic mutations in malignant tumours. [2]
- b) Knudson's two-hit hypothesis. [4]
- c) Testing for germ line and somatic mutations. [4]

Question Number: 3 Question Id: 32718720714 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Autophagy and its role in carcinogenesis. [3]

b) Constituent cell types of tumor microenvironment. [3]

c) Explain impact of tumour microenvironment for therapy of multiple myeloma. [4]

Question Number: 4 Question Id: 32718720715 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) List chemotherapeutic agents known to cause pulmonary toxicity. [3]

b) Mechanism of bleomycin induced pulmonary toxicity. [3]

c) Imaging features, and management of bleomycin induced pulmonary toxicity. [4]

Question Number: 5 Question Id: 32718720716 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

Mechanism of action, indications, and adverse effects of:

a) Inotuzumab ozogamicin. [5]

b) Polatuzumab vedotin. [5]

Question Number: 6 Question Id: 32718720717 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Enumerate epigenetic abnormalities in cancer and explain with examples. [5]

b) Name 2 drugs (based on epigenetic mechanism), their efficacy and side effects in the treatment

of hematological malignancies. [5]

Question Number: 7 Question Id: 32718720718 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Risk factors for prostate cancer. [3]

- b) Prostate specific antigen (PSA). [3]
- c) List investigations in a case of metastatic prostate cancer with rationale. [4]

Question Number: 8 Question Id: 32718720719 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) List the drugs used during induction therapy of acute lymphoblastic leukemia (ALL), and explain their mechanism of actions. [4]

- b) CNS prophylaxis in ALL. [3]
- c) Discuss briefly the pharmacogenomics of 6-MP (6-mercaptopurine) and 5-FU. [3]

Question Number: 9 Question Id: 32718720720 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time: 0

Correct Marks: 10

- a) Discuss Phase II clinical trials. [4]
- b) Cohort studies and their importance. [3]
- c) Seamless Phase II/III designs. [3]

Question Number: 10 Question Id: 32718720721 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Name common performance scores used in oncology both for adults and children, and describe one in each category. [4]

- b) Dose dense anticancer therapy with examples where it is useful and where it has failed. [3]
- c) How do you adjust drug dosing of anticancer drugs for obese patients and those with

